2004 (English)In: Current opinion in investigational drugs (London, England : 2000), ISSN 1472-4472, Vol. 5, no 4, 456-62 p.Article in journal (Refereed) Published
Palatin, under license from Competitive Technology, is developing the peptide PT-141, a synthetically modified analog of PT-14, as a nasal spray for the potential treatment of erectile dysfunction (ED) and female sexual dysfunction. In September 2003, Palatin had completed a phase IIb trial in patients with ED and in February 2004, Palatin planned to start phase III trials in early 2005.
Place, publisher, year, edition, pages
2004. Vol. 5, no 4, 456-62 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-77658PubMedID: 15134289OAI: oai:DiVA.org:liu-77658DiVA: diva2:528215